Inventiva S.A. Expected to Earn FY2025 Earnings of ($2.92) Per Share (NASDAQ:IVA)

Inventiva S.A. (NASDAQ:IVAFree Report) – Equities researchers at HC Wainwright upped their FY2025 EPS estimates for Inventiva in a research note issued on Monday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will earn ($2.92) per share for the year, up from their previous estimate of ($2.95). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Inventiva’s current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Inventiva’s FY2026 earnings at ($3.11) EPS and FY2027 earnings at ($2.67) EPS.

Other research analysts also recently issued research reports about the stock. Lifesci Capital restated an “outperform” rating on shares of Inventiva in a research report on Friday, January 5th. Stifel Nicolaus decreased their price target on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Inventiva has an average rating of “Buy” and an average price target of $15.67.

Check Out Our Latest Stock Report on Inventiva

Inventiva Stock Performance

Shares of Inventiva stock opened at $3.64 on Thursday. The company’s 50 day moving average is $3.72 and its 200 day moving average is $3.98. Inventiva has a twelve month low of $2.22 and a twelve month high of $5.05.

Hedge Funds Weigh In On Inventiva

Institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC lifted its position in Inventiva by 20.5% during the third quarter. Commonwealth Equity Services LLC now owns 24,435 shares of the company’s stock valued at $103,000 after purchasing an additional 4,155 shares during the last quarter. Citigroup Inc. lifted its position in Inventiva by 91.7% during the first quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock valued at $84,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Morgan Stanley lifted its position in Inventiva by 300.0% during the fourth quarter. Morgan Stanley now owns 6,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,500 shares during the last quarter. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Company Profile

(Get Free Report)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.

Featured Articles

Earnings History and Estimates for Inventiva (NASDAQ:IVA)

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.